Group 1: Industry Policy Dynamics - Recent active policy developments in the pharmaceutical industry may indirectly impact companies like Boji Pharmaceutical (300404) and other medical research outsourcing firms [1] - The National Health Commission approved a pilot program for internet-based pediatric specialty consultations in Beijing, marking a significant step towards the standardization of internet healthcare and potentially accelerating the online medical service process [1] - The National Medical Products Administration announced support for innovation in the biomanufacturing industry during the 14th Five-Year Plan, with a projected 17% year-on-year increase in the approval of innovative medical devices by 2025 [1] - Jiangsu Province's medical insurance bureau is advancing a policy to separate the budget for innovative drugs, which aims to alleviate budget constraints for hospitals in the first three years of negotiated drug prices [1] Group 2: Company Stock Performance - Boji Pharmaceutical's stock price has been fluctuating, closing at 10.56 yuan on February 13, 2026, down 1.31% for the day, with a trading volume of 70.75 million yuan [2] - Over the past five days (February 9 to 13), the stock experienced a price change of 0.38%, with a high of 10.82 yuan and a low of 10.48 yuan, resulting in a volatility of 3.23% [2] - On February 13, there was a net inflow of 4.217 million yuan from institutional investors, while retail investors showed a net outflow; technical indicators suggest a short-term consolidation phase [2] Group 3: Institutional Insights - Institutional interest in Boji Pharmaceutical is moderate, with recent sentiment being neutral; a report from Xiangcai Securities noted increased activity in the innovative drug supply chain, but the industry still faces pressure from medical insurance controls [3] - Multiple institutions forecast Boji Pharmaceutical's net profit to reach approximately 45 million yuan in 2025, representing a year-on-year growth of 56.38%, with an expected earnings per share of 0.12 yuan; projections for 2026 suggest a net profit of 66 million yuan and potential revenue expansion [3] - The company’s "Semaglutide Injection" project is currently in Phase III clinical trials, but specific timelines for progress remain unclear, necessitating attention to subsequent clinical results and their potential impact on performance [3]

Core Viewpoint - The company emphasizes its focus on core business operations and enhancing intrinsic value while managing market capitalization, indicating a commitment to improving operational quality as a central aspect of its market value management [2] Group 1 - The company has been actively engaging with investors through platforms to address inquiries and provide updates on its strategic focus [2] - The company acknowledges that its stock price in the secondary market is influenced by various factors, highlighting the complexity of market dynamics [2] - The company reiterates the importance of operational quality in its market value management strategy, suggesting a long-term vision for sustainable growth [2]

Core Viewpoint - The company, Boji Pharmaceutical, is experiencing a decline in net profit due to a decrease in overall gross margin influenced by intensified industry competition before the third quarter of 2025 [1] Group 1: Financial Performance - The company's net profit is expected to decline year-on-year due to a decrease in overall gross margin [1] - Management expense ratio and R&D expense ratio have both decreased before the third quarter of 2025 as a result of enhanced internal management and cost reduction efforts [1] Group 2: Strategic Focus - The company will continue to focus on its core business, primarily clinical operations, to enhance its core competitiveness [1] - The company aims to make every effort to improve operational performance [1]

Core Viewpoint - The company, Boji Pharmaceutical, emphasizes its competitive edge in traditional Chinese medicine (TCM) research and development services, focusing on providing comprehensive TCM R&D services and enhancing its capabilities in the field [1] Group 1: Business Focus - The company primarily offers TCM R&D services through its wholly-owned subsidiary, Xinglin TCM, which provides clinical, preclinical, and registration services for TCM [1] - The company’s controlling subsidiary, Henan Kangli, specializes in post-marketing re-evaluation services for TCM [1] Group 2: Research and Development Achievements - In the past two years, the company has successfully developed TCM Class 1.2 CRA (raw materials and formulations) and Class 1.1 Qingzhi ointment, both of which have received the "Drug Clinical Trial Approval Notice" [1] - Several innovative TCM self-research projects are currently in the preclinical development stage [1] Group 3: Future Strategy - The company plans to continue prioritizing TCM R&D services while supplementing its self-research efforts and aims to attract more TCM R&D talent to enhance its competitiveness in the TCM sector [1]

Investment Rating - The investment rating for the healthcare industry is "Positive" and maintained [14] Core Insights - The funding levels for Chinese innovative pharmaceutical companies are increasing, leading to a gradual improvement in the research and development (R&D) investment sentiment within the industry. This is expected to usher in a new cycle of prosperity for the innovative drug industry chain [5][12] - The trend of external business development (BD) is likely to benefit the domestic early-stage research industry significantly, as new business models allow early-stage projects to become tradable and monetizable assets, enhancing R&D investment returns [13] Summary by Sections Innovative Chain Development Review - Before 2020, multiple factors converged to initiate a significant rise in China's innovative drug sector, leading to the rapid development of the innovative chain, including CXO and life sciences services [10][30] - From 2020 to the first half of 2022, the global public health crisis accelerated capital inflow into the biopharmaceutical sector, resulting in high demand and a leap in the innovative chain segment, which also triggered a wave of IPOs and substantial supply-side expansion [10][39] - The second half of 2022 to 2024 saw a transition from a heated to a cooling phase, with a significant shift in supply-demand dynamics leading to industry internal competition and pressure on revenues and profit margins [10][54][57] Improvement in R&D Investment Sentiment - Starting from 2025, the R&D investment sentiment in China's innovative drug sector is expected to improve, with companies experiencing increased funding levels. The total amount raised through IPOs and additional offerings in 2025 is projected to reach 201.5 billion yuan, a 145% year-on-year increase [11][62] - The potential milestone payments from external BD are expected to reach 880.5 billion yuan in 2025, marking a 185.9% year-on-year increase, indicating a robust funding environment for innovative drug companies [11] Benefits to Early-stage Research Industry - The new external BD business model enhances the R&D investment return rates for Chinese innovative drug companies, thereby increasing their willingness to invest in R&D [11][13] - The early-stage research industry, including drug discovery CROs and clinical trial services, is expected to benefit significantly from the external BD trend, with leading companies in these segments poised for rapid growth [13]

Group 1 - The CRO index experienced a partial increase on January 30, with Tigermed leading the gains at 7.83% [1] - Other companies such as Nossan, Sunshine Nuohe, Boji Medical, and Baicheng Medical also saw increases, with respective gains of 5.88%, 1.41%, 0.85%, and 0.75% [1]

Group 1 - The company, Boji Pharmaceutical, is actively expanding its overseas clinical business by establishing subsidiaries abroad and forming an international business department [2] - The company is recruiting talent with international business experience to support its global expansion efforts [2]

Core Insights - The event "CGT Drug Development Full Chain" held in Chengdu aims to gather various stakeholders to discuss the innovation pathways in the cell and gene therapy (CGT) industry, contributing to the establishment of Chengdu as a significant biopharmaceutical hub in China [1][2] Group 1: Industry Context - The cell and gene therapy sector is experiencing dual opportunities from technological breakthroughs and policy support, as highlighted in China's "14th Five-Year Plan" for biopharmaceutical development [2] - The salon focuses on key issues across the entire CGT chain, providing a platform for local industry exchange and contributing to the high-quality development of the national CGT industry [2] Group 2: Expert Insights - Experts from various fields shared insights on regulatory review, clinical trial efficiency, commercialization management, international market access strategies, and innovative payment models, identifying pain points and challenges in the industry [3] - The consensus among experts is that achieving synergy across the entire chain from research and development to payment is crucial for the sustainable development of the CGT industry [3] Group 3: Collaborative Efforts - The event facilitated in-depth discussions among industry representatives, researchers, and experts on topics such as CGT technology iteration, clinical translation challenges, cost control, and payment model innovation, reflecting the active collaboration within Chengdu's CGT ecosystem [3] - The salon's comprehensive agenda covering "research-clinical-operation-export-payment" established a multi-perspective dialogue platform, enhancing ecological collaboration and resource integration in Chengdu's CGT industry [3]

Group 1 - The management of Boji Pharmaceutical expresses confidence in the company's long-term development and has never relaxed its efforts in operations and growth [1] - The company is focused on enhancing its profitability and is committed to returning value to investors through continuous dividends [1] - Boji Pharmaceutical aims to create long-term value for its investors [1]

Group 1 - The company, Boji Pharmaceutical, is actively monitoring technological developments in the forefront of the industry [2] - The company is making corresponding technological reserves to adapt to these advancements [2]